Loading clinical trials...

Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers | Clinical Trials | Clareo Health

COMPLETEDPHASE1

Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers

Clinical Validation of an Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers Indicating Cognitive Decline

NCT04567745•Mayo Clinic

View on ClinicalTrials.gov

Summary

This study aims to provide clinical validation of EyeQuant, a fully automated retinal image analysis system for computation of vascular biomarkers indicative of cognitive disorders, using retinal fundus photographs collected from patients with mild cognitive impairment, Alzheimer's disease, and vascular dementia.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•\- Patients older than 18 years and diagnosed with mild cognitive impairment (MCI), Alzheimer's disease (AD), or vascular cognitive impairment and/or dementia (VaD).
•Patients without the means to visit the clinic on the assigned dates.
•Patients who are pregnant or are expecting to become pregnant.

Locations (1)

Mayo Clinic Arizona

Scottsdale, Arizona, United States

Key Dates

Start Date

September 29, 2020

Primary Completion Date

September 30, 2021

Completion Date

September 30, 2021

Last Updated

November 1, 2021

Enrollment

ACTUAL participants

Conditions

Mild Cognitive ImpairmentAlzheimer DiseaseVascular Dementia

Interventions

Retinal fundus photography

DIAGNOSTIC_TEST

Sense4Safety Intervention

NCT07220668

Mild Cognitive Impairment

View study

RECRUITINGNA

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

NCT07178210

Alzheimer DiseaseLymphatic Obstruction

View study

RECRUITINGEARLY_PHASE1

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 1, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers

Inclusion Criteria

Sense4Safety Intervention

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

Validating the On-line Creyos Cognitive Assessment Platform in Older Adults With Major Depressive Disorder or Mild Cognitive Impairment

Effect of Striatal Temporal Interference Stimulation on Language Processing in Neurodegenerative Diseases